Available retrospective case series assessing anti-CTLA-4 treatment with pre-existing autoimmune disease has emerged in the melanoma literature with a trend toward increased occurrence and severity of irAE when compared with historical controls (81, 82). This evidence concerns the gene CTLA4 and melanoma.